US › Healthcare

BioRestorative Therapies Inc (BRTX)

US · Healthcare · Biotechnology

$0.21+6.11%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$23,170
Revenue YoY
-7.3%
Net profit
$-2.2M
Profit YoY
+59.7%
EPS
$-0.12
EPS estimate
$-0.30
Net margin
-9,298.3%

EPS came in at -0.12 against a street estimate of -0.30 — a beat of 60.0%.

Key statistics

Market cap
$5.0M
Forward P/E
0.0
P/B
1.72
Book value
$0.12
EPS (TTM)
$-1.06
52-week high
$1.89
52-week low
$0.16
50-day MA
$0.35
200-day MA
$0.68
Beta
0.74

Analyst view

Analysts rate BioRestorative Therapies Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $8.00.

Shareholding

Insiders
12.13%
Institutions
7.43%

Largest institutional holders

FundStake
Citadel Advisors Llc0.94%
Geode Capital Management, LLC0.88%
UBS Group AG0.39%
Wealth Alliance, LLC0.16%
Vanguard Fiduciary Trust Co0.15%
State Street Corp0.13%
Keystone Financial Group Inc0.11%
Advisor Group Holdings, Inc.0.01%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for BioRestorative Therapies Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.